Benefits of dark chocolate for Health
- By Medicine Mates
- Posted 1507 days ago
A single dose of dark chocolate increases parasympathetic modulation and heart rate variability in healthy subjects
Ana Amélia Machado DUARTE1
1Universidade Federal de Ciências da Saúde de Porto Alegre, Departamento de Ciências Básicas da Saúde, Programa de Pós-Graduação em Ciências da Saúde. R. Sarmento Leite, 245, Cidade Baixa, 90050170, Porto Alegre, RS, Brasil.
2Universidade Federal do Maranhão, Departamento de Educação Física, Programa de Mestrado em Saúde do Adulto e da Criança. São Luís, MA, Brasil.
3Universidades de São Paulo, Instituto do Coração, Unidade de Hipertensão. São Paulo, SP, Brasil.
The aim of this study was to investigate the acute effect of a single dose of dark chocolate (70% cocoa) on blood pressure and heart rate variability.
Thirty-one healthy subjects (aged 18-25 years; both sexes) were divided into two groups: 10 subjects in the white chocolate (7.4 g) group and 21 in the dark chocolate (10 g) group; measurements were performed at the university's physiology lab. An electrocardiogram measured the sympathovagal balance by spectral and symbolic analysis.
A single dose of dark chocolate significantly reduced systolic blood pressure and heart rate. After consuming 10 g of dark chocolate, significant increases were observed for heart rate variability, standard deviation of RR intervals standard deviation of all NN intervals, square root of the mean squared differences between adjacent normal RR intervals root mean square of successive differences, and an increase in the high frequency component in absolute values, representing the parasympathetic modulation.
In conclusion the importance of our results lies in the magnitude of the response provoked by a single dose of cocoa. Just 10 g of cocoa triggered a significant increase in parasympathetic modulation and heart rate variability. These combined effects can potentially increase life expectancy because a reduction in heart rate variability is associated with several cardiovascular diseases and higher mortality.
Keywords: Autonomic nervous system; Cocoa; Flavonoids.
Studies indicate that consumption of foods rich in polyphenols is associated with lower risk of disease1,2 and consequently, with a decreased risk of morbidity and mortality3. Cocoa products, such as dark chocolate, which are rich in polyphenols, have demonstrated beneficial effects, particularly on the cardiovascular system4,5.
Protection of the cardiovascular system by cocoa, present in dark chocolate, stems from several effects, such as antioxidant6, antiatherosclerotic7,8, anti-inflammatory9,10 and platelet anti-aggregation effects11, and reduced Angiotensin-Converting Enzyme (ACE) activity12, among others. Improvements in nitric oxide bioavailability13 and endothelial function14 have also been reported, and ultimately, these changes lead to vascular relaxation and antihypertensive effects15,16. On the other hand, there is no published data associating cocoa consumption and autonomic nervous system modulation.
One of the mechanisms that improves Blood Pressure (BP) control could be associated with the peripheral afferent nerve fibers that carry BP information to the central nervous system. This mechanism includes the sympathetic and/or parasympathetic activation that changes Heart Rate (HR) to promote BP stabilization17. Heart Rate Variability (HRV) has been studied for the last few decades18 to assess the autonomic modulation of the cardiovascular system19,20. Good BP adaptation is an indication of high HRV, whereas lower HRV is frequently an indicator of abnormal and/or insufficient adaptation of cardiac Autonomic Nervous System (ANS) modulation21.
In fact the cardiovascular and autonomic functions of hypercholesterolemic rabbits treated chronically with cocoa liquor were preserved. Additionally, baroreflex regulation improved. These authors also observed that parasympathetic modulation was preserved in the group that consumed cocoa liquor, differently from the control group, which experienced lower cardiac parasympathetic22 modulation.
It is well described in the literature that there is an increase in sympathetic modulation in most diseases. Sympathetic modulation is associated with worse prognosis and increased mortality23. Thus, chocolate consumption is simple and easy to do, and its potential impact over autonomic modulation makes it a preventive and nonpharmacological strategy.
However, no study was found in the literature that described the effect of a single dose of dark chocolate on the modulation of the autonomic nervous system in experimental models or subjects. The result of this study highlights the potential effects of cocoa intake and draw attention to the importance of regular cocoa consumption in small doses. Thus, the aim of this study was to investigate the effect of dark chocolate intake on BP and HRV in healthy individuals.
The protocol was approved by the Ethics Committee of Universidade Federal de Ciências da Saúde de Porto Alegre(UFCSPA, Federal University of Health Sciences of Porto Alegre) nº 075/05. The study was conducted in 2013 at the physiology laboratory of said university. Thirty-one UFCSPA students aged 18-25 years were invited to participate in the study. After signing the informed consent, the subjects were randomly allocated into one of the two groups. All subjects included were clinically healthy, non-obese, normotensive, and nonsmokers, but they did not exercise regularly. They were not taking any antioxidant supplements or medications, except oral contraceptives. In women all measurements were collected during the early follicular phase (days 1-3) of the menstrual cycle24.
The subjects entered a further cocoa-free washout phase of 7 days, according to the protocol described by Taubert and coworkers25. For 24 hours before the experiment, the volunteers were instructed to abstain from drinking alcohol or caffeinated products, and exercising.
The dark chocolate group received 10 g of dark chocolate (Lugano(r), Gramado, RS, Brazil) with 70% cocoa. The dark chocolate had the following composition (10g): energy=54.4 Kcal, carbohydrates=4 g, total fats=3.6 g, proteins=0.8 g, sodium=0 mg, dietary fibers=0.8 g, and total flavonoids/epicatechin=5.41 mg.
The white chocolate group received 7 g of white chocolate (Laka, Lacta(r) Curitiba, PR, Brazil) containing the same amount of sugar as the 10 g of dark chocolate. The white chocolate composition (7g) was as follows: energy=38.08 Kcal, carbohydrates=4.2 g, total fats=2.1 g, proteins=0.5 g, sodium=12.32 mg, dietary fibers=0 g, and total flavonoids/epicatechin=0 mg.
Experimental sequence were as follows: 1) BP, HR and HRV were measured at rest; 2) the subjects consumed chocolate (white or dark); 3) anthropometric data were collected immediately after the chocolate intake; 4) One hour after chocolate intake, a second set of BP, HR and HRV measurements were performed, also at rest.
The subjects were seated in an upright position with back support and were asked to relax for 5 min. Blood pressure was measured by an automatic digital device (Omron(r), IntelliSense, BP785, Bannockburn, Illinois, USA). The blood pressure cuff covered at least 80% of the upper arm. To confirm the data, BP was measured three times at 2- minute intervals. When a difference of more than 6 mmHg between measurements was detected, the measurements were repeated until the difference was less than 4 mmHg. The participants' BP, Mean BP (MBP), HR, and Pulse Pressure (PP) were given by averaging the three BP measurements.
Heart rate variability
An Electrocardiogram (ECG) signal was acquired at a 1 kHz sampling rate for a 10-minute period with the subject in the supine position and head elevation of 30°. The protocol used three ECG derivations. To assess the HRV, the temporal series of RR intervals were registered and processed by the MP150 system (Biopac, California, United States of America).
The temporal series were analyzed by the program Matlab, in which the ECG signal was processed to obtain the variables related to HRV in the time and frequency domains. The Standard Deviation of all NN (SDNN) intervals and the Root Mean Square of Successive Differences (RMSSD) between adjacent normal RR intervals and the square root of the mean squared differences between adjacent normal RR intervals (RMSSD) were chosen as the variables in the time domain, expressed in meter per second. In the frequency domain, analysis of HRV was performed by Fast Fourier Transform (FFT) in portions of 5 minutes with 4 Hz interpolation and an overlap of 50%. The low frequency (LF; 0.04 to 0.15 Hz; this component predominantly corresponds to sympathetic modulation) and high frequency (HF; 0.15 to 0.4 Hz; corresponds to parasympathetic modulation) components were presented in absolute (Low Frequency absolut (LFa) and High Frequency absolut (HFa) and normalized Low Frequency normalised units (LFnu) and High Frequency normalised units (HFnu). Normalized units were obtained by dividing the power of a given component by the total power (from which Very Low Frequency [VLF] was subtracted) and multiplying by 100. The ratio between absolute values (LF/HF) was used as an index of cardiac autonomic modulation26.
Symbolic analysis is a powerful and validated tool to detect changes in autonomic modulation of cardiovascular variability27, which transforms a time series into short, three-beat patterns. It was carried out according to the approach previously described and validated by Porta et al.28. However, the data were adjusted into three groups instead of four in accordance with Guzzetti et al.29.
The sequences are spread on six levels, and all possible patterns are divided into four groups, consisting of patterns with: 1) No Variations (0V, three symbols equal); 2) One Variation (1V, two equal symbols and one different); 3) Two Like Variations (2LV); and 4) Two Unlike Variations (2UV)29.
The data were analyzed by repeated measures Analysis of Variance (ANOVA) followed by the Mann-Whitney and Wilcoxon tests. The data are presented as mean ± Standard Deviation (SD), and p<0.05 was considered statistically significant.
The subjects were 22±2 years old, and the Body Mass Index (BMI) was 22.5±3 kg/m2. Systolic Blood Pressure (SBP) and HR decreased significantly after dark chocolate intake. On the other hand, Diastolic Blood Pressure (DBP), MAP, and PP did not change in either group (Table 1).
Table 1 Hemodynamic values before and after chocolate intake.
Note: * p<0.05. Data expressed as means (M) ± Standard Deviation (SD).
SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; MBP: Mean Blood Pressure; PP: Pulse Pressure; HR: Heart Rate.
In the time domain, spectral analyses showed that a single dose of dark chocolate significantly increased the total power of HRV, SDNN, and RMSSD. In addition, in the frequency domain, there was a significant increase only in the HFa component (ms2; Table 2). Collectively, these results indicate a significant predominance of the parasympathetic system after dark chocolate intake. Table 2 shows the symbolic analysis results (%). Symbolic analysis found no significant difference between the groups after chocolate intake.
Table 2 Spectral and symbolic analysis data before and after chocolate intake.
Note: * p<0.05. Spectral analysis results.
HRV: Heart Rate Variability; SDNN: Standard Deviation of Normal RR Intervals; RMSSD: Square Root of the Mean Squared differences between consecutive RR intervals; LF: Low Frequency Component; HF: High Frequency Component; a: Absolute; nu: Normalized. LF/HF ratio: sympathovagal balance; V: Variation. Data expressed as Means (M) and ± Standard Deviation (SD); 0V: No Variations (three symbols equal and indicate sympathetic modulation); 1V: One Variation (two symbols equal and one different. Indicate both sympathetic and parasympathetic modulation); 2LV: Two Like Variations and indicate parasympathetic modulation; and 2ULV: Two Unlike Variations and indicate parasympathetic modulation.
The most significant observation of this study is that a single dose of 10 g of dark chocolate improves cardiac Autonomic Nervous System (ANS) modulation in healthy subjects. After one hour, dark chocolate intake significantly increased (200%) HRV total power and improved parasympathetic modulation, seen by spectral analysis. On the other hand, no difference was observed after chocolate intake by symbolic analysis. Although the mechanism still remains under investigation, recent studies have suggested that chronic dark chocolate intake decreases BP13,15,30, 31 and SBP25,32, improves endothelial function in healthy subjects32-36 , and reduces both systolic and DBP in soccer players37. The present study only found a reduction in the SBP of healthy individuals.
In addition, acute cocoa intake improves endothelial function and BP in smokers38 and overweight subjects39. Moreover, it also improves flow-mediated dilatation in patients with peripheral artery disease40.
According to Sudarma et al.41, flavonols may explain BP improvement as they have been shown to stimulate endothelial nitric oxide production and thus cause blood vessel dilatation in prehypertensive subjects. This conclusion is also supported by Flammer et al.42, who had shown that a single dose of dark chocolate improved coronary vascular function and decreased platelet adhesion and serum oxidative stress, probably correlated to serum epicatechin level.
In fact epidemiological studies indicate that, at least partially, the good effects of flavonoids are due to their antioxidant and anti-inflammatory properties. Consumption of flavonoids, also present in cocoa, is associated with better cognitive performance43 and lower risk of neurodegenerative disorders in older adults44. Collectively, these findings enhance the beneficial effects of cocoa on the central nervous system and, as seen by our results, its strong impact on the autonomic nervous system and cardiovascular function.
The importance of our results lies in the magnitude of the response provoked by a single dose of cocoa. Even being a nonpharmacological intervention, less than 10 g of cocoa triggered a significant increase in cardiac parasympathetic modulation and HRV. These combined effects can potentially increase life expectancy45 because a decrease in HRV is associated with several cardiovascular diseases18, and increased cardiovascular risk and mortality46-48. Our results were surprising because single nonpharmacological interventions usually have little physiological effect.
Thus, although it is very well established in the literature that chronic dark chocolate intake is beneficial for BP control, our results are the first demonstrating the improvement in autonomic modulation. The antioxidant properties of cocoa are probably what improve BP control, centrally and peripherally. The magnitude of their effect can be demonstrated by the increase in heart rate variability.
Moreover, in the time domain, dark, but not white, chocolate intake increases all parameters: SDNN, RMSSD, and HRV. In the frequency domain, there was also an increase in parasympathetic modulation, seen by HF in absolute values; and the symbolic analysis showed that dark chocolate decreased sympathetic modulation.
Furthermore, sympathetic predominance increases plasma angiotensin II49, which leads to an increase in Nicotinamide Adenine Dinucleotide Phosphate (NADPH), oxidase activity, and superoxide anion formation. The increase in superoxide anion induces oxidative stress50, which, ultimately, decreases nitric oxide bioavailability40, and its effects probably impair cardiac autonomic modulation and BP control.
Our results are supported also by Villarreal Calderon et al.51, who showed a neuroprotective effect of chocolate. They found that, in mice subjected to urban air pollution, chocolate intake mitigated vagal inflammation, supporting the idea that cocoa may improve nervous system function.
These results demonstrate that a single dose of dark chocolate improves the HRV and reduces SBP and HR. Collectively, these results reinforce the importance of consuming dark chocolate to prevent cardiovascular diseases and highlight the fact that a small dose can be of impact to induce benefits that are not seen by white chocolate intake. Improvement in the sympathovagal balance, seen by higher HRV after dark chocolate, but not white chocolate intake, was responsible for better cardiovascular system control and probably can be attributed to the flavonoids of the cocoa. Thus, it is reasonable to believe that dark chocolate represents a valuable option that might promote health and reduce cardiovascular risk and mortality. A randomized, controlled clinical trial of the population's life expectancy would be very useful to demonstrate the beneficial effects of daily dark chocolate intake on autonomic modulation, as seen from heart rate variability.
This study was sponsored by Coordenação de Aperfeiçoamento de Pessoal de Nível Superior and the Lugano Chocolate Company, which provided the dark chocolate (70% cocoa).
1. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: The Zutphen Elderly Study. Lancet. 1993; 342(8878):1007-11. [ Links ]
2. Manach C, Mazur A, Scalbert A. Polyphenols and prevention of cardiovascular diseases. Curr Opin Lipidol. 2005; 16(1):77-84. [ Links ]
3. Keli SO, Hertog MG, Feskens EJ, Kromhout D. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: The Zutphen study. Arch Intern Med. 1996; 156(6):637-42. [ Links ]
4. Corti R, Flammer AJ, Hollenberg NK, Luscher TF. Cocoa and cardiovascular health. Circulation. 2009; 119(10):1433-41. [ Links ]
5. Buijsse B, Weikert C, Drogan D, Bergmann M, Boeing H. Chocolate consumption in relation to blood pressure and risk of cardiovascular disease in German adults. Eur Heart J. 2010; 31(13):1616-23. [ Links ]
6. Serafini M, Bugianesi R, Maiani G, Valtuena S, De Santis S, Crozier A. Plasma antioxidants from chocolate. Nature. 2003; 424(6952):1013. [ Links ]
7. Kondo K, Hirano R, Matsumoto A, Igarashi O, Itakura H. Inhibition of LDL oxidation by cocoa. Lancet. 1996; 348(9040):1514. [ Links ]
8. Baba S, Natsume M, Yasuda A, Nakamura Y, Tamura T, Osakabe N, et al. Plasma LDL and HDL cholesterol and oxidized LDL concentrations are altered in normo- and hypercholesterolemic humans after intake of different levels of cocoa powder. J Nutr. 2007; 137(6):1436-41. [ Links ]
9. Selmi C, Cocchi CA, Lanfredini M, Keen CL, Gershwin ME. Chocolate at heart: The anti-inflammatory impact of cocoa flavanols. Mol Nutr Food Res. 2008; 52(11):1340-8. [ Links ]
10. Mao TK, Powell J, van de Water J, Keen CL, Schmitz HH, Hammerstone JF, et al. The effect of cocoa procyanidins on the transcription and secretion of interleukin 1 beta in peripheral blood mononuclear cells. Life Sci. 2000; 66(15):1377-86. [ Links ]
11. Bordeaux B, Yanek LR, Moy TF, White LW, Becker LC, Faraday N, et al. Casual chocolate consumption and inhibition of platelet function. Prev Cardiol. 2007; 10(4):175-80. [ Links ]
12. Persson IA, Persson K, Hagg S, Andersson RG. Effects of cocoa extract and dark chocolate on angiotensin-converting enzyme and nitric oxide in human endothelial cells and healthy volunteers-a nutrigenomics perspective. J Cardiovasc Pharmacol. 2011; 57(1):44-50. [ Links ]
13. Taubert D, Roesen R, Lehmann C, Jung N, Schomig E. Effects of low habitual cocoa intake on blood pressure and bioactive nitric oxide: A randomized controlled trial. JAMA. 2007; 298(1):49-60. [ Links ]
14. Vlachopoulos C, Aznaouridis K, Alexopoulos N, Economou E, Andreadou I, Stefanadis C. Effect of dark chocolate on arterial function in healthy individuals. Am J Hypertens. 2005; 18(6):785-91. [ Links ]
15. Desch S, Schmidt J, Kobler D, Sonnabend M, Eitel I, Sareban M, et al. Effect of cocoa products on blood pressure: Systematic review and meta-analysis. Am J Hypertens. 2010; 23(1):97-103. [ Links ]
16. Mehrinfar R, Frishman WH. Flavanol-rich cocoa: A cardioprotective nutraceutical. Cardiol Rev. 2008; 16(3):109-15. [ Links ]
17. Franchini KG, Cowley AW, Jr. Sensitivity of the renal medullary circulation to plasma vasopressin. Am J Physiol. 1996; 271(3Pt 2):R647-53. [ Links ]
18. Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J. 1996; 17(3):354-81. [ Links ]
19. Bertagnolli M, Schenkel PC, Campos C, Mostarda CT, Casarini DE, Bello-Klein A, et al. Exercise training reduces sympathetic modulation on cardiovascular system and cardiac oxidative stress in spontaneously hypertensive rats. Am J Hypertens. 2008; 21(11):1188-93. [ Links ]
20. Tobaldini E, Porta A, Wei SG, Zhang ZH, Francis J, Casali KR, et al. Symbolic analysis detects alterations of cardiac autonomic modulation in congestive heart failure rats. Auton Neurosci. 2009; 150(1-2):21-6. [ Links ]
21. Pumprla J, Howorka K, Groves D, Chester M, Nolan J. Functional assessment of heart rate variability: Physiological basis and practical applications. Int J Cardiol. 2002; 84(1):1-14. [ Links ]
22. Akita M, Kuwahara M, Itoh F, Nakano Y, Osakabe N, Kurosawa T, et al. Effects of cacao liquor polyphenols on cardiovascular and autonomic nervous functions in hypercholesterolaemic rabbits. Basic Clin Pharmacol Toxicol. 2008; 103(6):581-7. [ Links ]
23. Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev. 2010; 90(2):513-57. [ Links ]
24. Minson CT, Halliwill JR, Young TM, Joyner MJ. Influence of the menstrual cycle on sympathetic activity, baroreflex sensitivity, and vascular transduction in young women. Circulation. 2000; 101(8):862-8. [ Links ]
25. Taubert D, Berkels R, Roesen R, Klaus W. Chocolate and blood pressure in elderly individuals with isolated systolic hypertension. JAMA. 2003; 290(8):1029-30. [ Links ]
26. Montano N, Porta A, Cogliati C, Costantino G, Tobaldini E, Casali KR, et al. Heart rate variability explored in the frequency domain: A tool to investigate the link between heart and behavior. Neurosci Biobehav Rev. 2009;33(2):71-80. [ Links ]
27. Porta A, Faes L, Masé M, D'Addio G, Pinna GD, Maestri R, et al. An integrated approach based on uniform quantization for the evaluation of complexity of short-term heart period variability: Application to 24 h Holter recordings in healthy and heart failure humans. Chaos. 2007; 17(1):015117. [ Links ]
28. Porta A, Tobaldini E, Guzzetti S, Furlan R, Montano N, Gnecchi-Ruscone T. Assessment of cardiac autonomic modulation during graded head-up tilt by symbolic analysis of heart rate variability. Am J Physiol Heart Circ Physiol. 2007; 293(1):H702-8. [ Links ]
29. Guzzetti S, Borroni E, Garbelli PE, Ceriani E, Della Bella P, Montano N, et al. Symbolic dynamics of heart rate variability: A probe to investigate cardiac autonomic modulation. Circulation. 2005;112(4):465-70. [ Links ]
30. Egan BM, Laken MA, Donovan JL, Woolson RF. Does dark chocolate have a role in the prevention and management of hypertension?: Commentary on the evidence. Hypertension. 2010; 55(6):1289-95. [ Links ]
31. Zomer E, Owen A, Magliano DJ, Liew D, Reid CM. The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: Best case scenario analysis using a Markov model. BMJ. 2012; 344:e3657. [ Links ]
32. Grassi D, Lippi C, Necozione S, Desideri G, Ferri C. Short-term administration of dark chocolate is followed by a significant increase in insulin sensitivity and a decrease in blood pressure in healthy persons. Am J Clin Nutr. 2005; 81(3):611-4. [ Links ]
33. Engler MB, Engler MM, Chen CY, Malloy MJ, Browne A, Chiu EY, et al. Flavonoid-rich dark chocolate improves endothelial function and increases plasma epicatechin concentrations in healthy adults. J Am Coll Nutr. 2004; 23(3):197-204. [ Links ]
34. Fisher ND, Hughes M, Gerhard-Herman M, Hollenberg NK. Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans. J Hypertens. 2003; 21(12):2281-6. [ Links ]
35. Ried K, Sullivan T, Fakler P, Frank OR, Stocks NP. Does chocolate reduce blood pressure? A meta-analysis. BMC Med. 2010; 8:39. [ Links ]
36. Heiss C, Schroeter H, Balzer J, Kleinbongard P, Matern S, Sies H, et al. Endothelial function, nitric oxide, and cocoa flavanols. J Cardiovasc Pharmacol. 2006; 47 (Suppl 2:S128-35):S72-6. [ Links ]
37. Fraga CG, Actis-Goretta L, Ottaviani JI, Carrasquedo F, Lotito SB, Lazarus S, et al. Regular consumption of a flavanol-rich chocolate can improve oxidant stress in young soccer players. Clin Dev Immunol. 2005; 12(1):11-7. [ Links ]
38. Heiss C, Dejam A, Kleinbongard P, Schewe T, Sies H, Kelm M. Vascular effects of cocoa rich in flavan-3-ols. JAMA. 2003; 290(8):1030-1. [ Links ]
39. Faridi Z, Njike VY, Dutta S, Ali A, Katz DL. Acute dark chocolate and cocoa ingestion and endothelial function: A randomized controlled crossover trial. Am J Clin Nutr. 2008; 88(1):58-63. [ Links ]
40. Loffredo L, Perri L, Catasca E, Pignatelli P, Brancorsini M, Nocella C, et al. Dark chocolate acutely improves walking autonomy in patients with peripheral artery disease. J Am Heart Assoc. 2014; 3(4):e001072. http://dx.doi.org/10.1161/JAHA.114.001072 [ Links ]
41. Sudarma V, Sukmaniah S, Siregar P. Effect of dark chocolate on nitric oxide serum levels and blood pressure in prehypertension subjects. Acta Med Indones. 2011; 43(4):224-8. [ Links ]
42. Flammer AJ, Hermann F, Sudano I, Spieker L, Hermann M, Cooper KA, et al. Dark chocolate improves coronary vasomotion and reduces platelet reactivity. Circulation. 2007; 116(21):2376-82. [ Links ]
43. Nurk E, Refsum H, Drevon CA, Tell GS, Nygaard HA, Engedal K, et al. Intake of flavonoid-rich wine, tea, and chocolate by elderly men and women is associated with better cognitive test performance. J Nutr. 2009; 139(1):120-7. [ Links ]
44. Letenneur L, Proust-Lima C, Le Gouge A, Dartigues JF, Barberger-Gateau P. Flavonoid intake and cognitive decline over a 10-year period. Am J Epidemiol. 2007; 165(12):1364-71. [ Links ]
45. Hollenberg NK, Fisher ND, McCullough ML. Flavanols, the Kuna, cocoa consumption, and nitric oxide. J Am Soc Hypertens. 2009; 3(2):105-12. [ Links ]
46. Tsuji H, Larson MG, Venditti FJ, Manders ES, Evans JC, Feldman CL, et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation. 1996; 94(11):2850-5. [ Links ]
47. Nolan J, Batin PD, Andrews R, Lindsay SJ, Brooksby P, Mullen M, et al. Prospective study of heart rate variability and mortality in chronic heart failure: Results of the United Kingdom heart failure evaluation and assessment of risk trial (UK-heart). Circulation. 1998; 98(15):1510-6. [ Links ]
48. Dekker JM, Crow RS, Folsom AR, Hannan PJ, Liao D, Swenne CA, et al. Low heart rate variability in a 2-minute rhythm strip predicts risk of coronary heart disease and mortality from several causes: The ARIC Study. Atherosclerosis Risk In Communities. Circulation. 2000; 102(11):1239-44. [ Links ]
49. Ajayi AAL, Hercule HC, Pamugo J, Dixon D, Oyekan AO. Interactions of the renin-angiotensin system and alpha-1 adrenoceptors on renal hemodynamics in healthy and acute renal failure rats: The role of nitric oxide. Blood Press. 2001; 10(4):238-46. [ Links ]
50. Kim M, Han CH, Lee MY. NADPH oxidase and the cardiovascular toxicity associated with smoking. Toxicol Res. 2014; 30(3):149-57. [ Links ]
51. Villarreal-Calderon R, Torres-Jardón R, Palacios-Moreno J, Osnaya N, Pérez-Guillé B, Maronpot RR, et al. Urban air pollution targets the dorsal vagal complex and dark chocolate offers neuroprotection. Int J Toxicol. 2010; 29(6):604-15 [ Links ]
2Article based on the doctoral dissertation of AAM DUARTE, entitled "Efeito agudo da ingestão de chocolate amargo na modulação do sistema nervoso simpático e parassimpático". Universidade Federal de Ciências da Saúde de Porto Alegre; 2013.
Table 1, “White chocolate (n=21)” should read “Dark chocolate (n=21)”.
Table 2, “White chocolate (n=21)” should read “Dark chocolate (n=21)”
Correspondência para/Correspondence to: AAM DUARTE. E-mail: <email@example.com>.CONTRIBUTORS
The authors C MOSTARDA and CM IRIGOYEN contributed to data analysis, and the authors AAM DUARTE and K RIGATTO contributed to study conception and design, and data analysis and interpretation. The article is based on a master's thesis.
On-line version ISSN 1678-9865
Rev. Nutr. vol.29 no.6 Campinas Nov./Dec. 2016
Av. John Boyd Dunlop, s/n. - Prédio de Odontologia
13059-900 Campinas - SP Brasil
Tel./Fax: +55 19 3343-6875